PRESS RELEASE
Stockholm, 16th of April 2013
Stille invests in solutions for smart instrument tracking
Stille AB has signed an intentional agreement to acquire 50% of the shares in the Danish company
Caretag Aps. Caretag develops and offers unique solutions for individual asset tracking and tracebility
of surgical and reprocessed instruments based on RFID technology.
”This is a very exciting alliance combining the best of two worlds. We’re creating a company that offers the
market a unique solution based on Caretag’s technical platform and Stille’s know-how in quality surgical
instruments.” Comments Philip Siberg, President and CEO of Stile. “This investment represents the first step
for Stille in meeting the increased demands for smart instruments and independent tracking systems with the
goal of increasing traceability, hospital process efficiency and patient safety.”
A hospital sterilizes often more thn 30.000 medical devices every day. The process steps include multiple
manual and cumbersome protocols and routines. Hospitals report that large quantities of instruments are lost
every year and they lack systems for individual tracking and safety control.
Caretag develops and implements solutions for individual micro radio based RFID tracking of instruments and
other resterilized devices. Caretag’s Asset Management System which is based on a hard- and software
platform identifies and tracks the hospital’s devices in real time. Caretag has successfully sold the modular
system to hospitals in Europe to enable more efficient process flows, control within and between operating
rooms and sterility departments, to ensure the right products are packed for the right procedures and verify
that each single product has been serviced according to its intended use and care.
”By partnering with Stille, we now have the opportunity to realize our vision to make hospitals more efficient
and safer through smart instruments and individual traceability. With Stille’s global network, strong brand and
unique production processes, we create a unique company with the technology of the future, which is already
here, and proven to stay.” Comments Michael Leibig, CEO of Caretag.
The market for RFID tracking of medical devices is expected to grow from USD 450 million in 2012 to USD
1,2 billion in 2018, corresponding to a growth rate of 17 percent.
Caretag Aps targets health care markets and is currently a subsidiary of Caretag Holding AB. Michael Leibig
is the CEO. The company will be renamed to Caretag Surgical Aps upon closing and Stille will assume Board
seats. Stille has warrants to acquire additional shares of the company and the final closing is expected with a
month from today’s date. No financial details are disclosed.
For more info, please contact:
Philip Siberg
CEO Stille AB
+46 70 790 6734
Stille AB (publ) utvecklar, tillverkar och marknadsför medicintekniska produkter för specialistkirurger världen över. Stille grundades 1841 och har utvecklat,
tillverkat och marknadsfört högkvalitativa kirurgiska instrument sedan dess och är därmed ett av världens äldsta företag inom medicinteknik. Stilles
prioriterade områden är kirurgiska instrument och specialbord för hjärt-/kärlkirurgi, plastikkirurgi och gynekologi/urologi. Bolaget har en stabil bas med ett
starkt varumärke och välkända produkter av erkänt hög kvalitet. Verksamheten bedrivs i två affärsområden, Kirurgi och Patientpositionering. Bolaget
fokuserar på att tillhandahålla produkter som genom sin design, sina funktioner, sin kvalitet och sin känsla skall ge läkaren möjlighet att ge en effektivare och
säkrare vård för dennes patienter. Under 2012 omsatte koncernen cirka 90 MSEK och hade 52 anställda. Aktien är noterad på marknadsplatsen First North
under kortnamnet ”STIL” med Remium som Certified Adviser. Besök även www.stille.se
Stille AB │ Gustav III:s Boulevard 42│ 169 73 Solna │ Tel +46 (0)8 588 580 00│Fax +46 (0)8 588 580 05│ www.stille.se